

NEOTHERAPEUTICS INC  
Form 8-K  
October 01, 2002

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

**Date of Report (Date of earliest event reported):**  
September 30, 2002

**NEOTHERAPEUTICS, INC.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction of  
Incorporation)

**000-28782**  
(Commission  
File Number)

**93-0979187**  
(I.R.S. Employer  
Identification No.)

**157 Technology Drive**  
**Irvine, California 92618**  
(Address of Principal Executive Offices)

---

**(949) 788-6700**  
(Registrant's telephone number, including area code)

---

**ITEM 5. OTHER EVENTS**

On October 1, 2002, NeoTherapeutics, Inc. (the Company ) issued a press release announcing that it has signed an agreement with GPC Biotech AG to co-develop NeoTherapeutics' lead anti-cancer drug satraplatin. The text of the press release is set forth in Exhibit 99.1 attached to this report and incorporated herein by this reference.

**ITEM 7. EXHIBITS**

**Exhibits:**

---

99.1 Press release dated October 1, 2002.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 1, 2002

NEOTHERAPEUTICS, INC.

By:                   /s/ Rajesh Shrotriya

**Name: Rajesh C.  
Shrotriya, M.D.  
Title: Chairman of the  
Board, Chief  
Executive Officer and  
President**

**EXHIBIT INDEX**

**Exhibits:**

---

99.1 Press release dated October 1, 2002.